Phase I/II randomized double-blind study of the safety and immunogenicity of a nonadjuvanted vero cell culture-derived whole-virus H9N2 influenza vaccine in healthy adults.
about
Emerging Influenza Strains in the Last Two Decades: A Threat of a New Pandemic?Refining the approach to vaccines against influenza A viruses with pandemic potential.Comparative Safety of Vaccine Adjuvants: A Summary of Current Evidence and Future NeedsVaccination against H9N2 avian influenza virus reduces bronchus-associated lymphoid tissue formation in cynomolgus macaques after intranasal virus challenge infection.Vero cell technology for rapid development of inactivated whole virus vaccines for emerging viral diseases.
P2860
Phase I/II randomized double-blind study of the safety and immunogenicity of a nonadjuvanted vero cell culture-derived whole-virus H9N2 influenza vaccine in healthy adults.
description
2014 nî lūn-bûn
@nan
2014 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Phase I/II randomized double-b ...... nza vaccine in healthy adults.
@ast
Phase I/II randomized double-b ...... nza vaccine in healthy adults.
@en
type
label
Phase I/II randomized double-b ...... nza vaccine in healthy adults.
@ast
Phase I/II randomized double-b ...... nza vaccine in healthy adults.
@en
prefLabel
Phase I/II randomized double-b ...... nza vaccine in healthy adults.
@ast
Phase I/II randomized double-b ...... nza vaccine in healthy adults.
@en
P2093
P2860
P356
P1476
Phase I/II randomized double-b ...... nza vaccine in healthy adults.
@en
P2093
Barbara Grohmann-Izay
Daniel Portsmouth
Gerald Aichinger
Maikel V W van der Velden
Manuela Koska
Mary Kate Hart
Otfried Kistner
P Noel Barrett
Sandor Fritsch
Wael El-Amin
P2860
P356
10.1128/CVI.00275-14
P577
2014-10-29T00:00:00Z